Current Report Filing (8-k)
February 10 2020 - 7:26AM
Edgar (US Regulatory)
false
0001578845
0001578845
2020-02-10
2020-02-10
0001578845
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
2020-02-10
2020-02-10
0001578845
agn:FloatingRateNotesDue2020Member
2020-02-10
2020-02-10
0001578845
agn:M0500NotesDue2021Member
2020-02-10
2020-02-10
0001578845
agn:M1500NotesDue2023Member
2020-02-10
2020-02-10
0001578845
agn:M1250NotesDue2024Member
2020-02-10
2020-02-10
0001578845
agn:M2625NotesDue2028Member
2020-02-10
2020-02-10
0001578845
agn:M2125NotesDue2029Member
2020-02-10
2020-02-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________________________________________________________
FORM 8-K
___________________________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 10, 2020 (February 10, 2020)
___________________________________________________________
ALLERGAN PLC
(Exact Name of Registrant as Specified in Charter)
___________________________________________________________
|
Ireland
|
|
001-36867
|
|
98-1114402
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
Clonshaugh Business and Technology Park
Coolock, Dublin, D17 E400, Ireland
(Address of Principal Executive Offices)
(862) 261-7000
(Registrant’s telephone number, including area code)
___________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
|
Securities registered pursuant to Section 12(b) of the Exchange Act:
|
|
|
|
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
|
Ordinary Share, par value $0.0001 per share
|
AGN
|
New York Stock Exchange
|
|
Floating rate notes due 2020
|
AGN20A
|
New York Stock Exchange
|
|
0.500% notes due 2021
|
AGN21
|
New York Stock Exchange
|
|
1.500% notes due 2023
|
AGN23A
|
New York Stock Exchange
|
|
1.250% notes due 2024
|
AGN24A
|
New York Stock Exchange
|
|
2.625% notes due 2028
|
AGN28
|
New York Stock Exchange
|
|
2.125% notes due 2029
|
AGN29
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
|
|
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On February 10, 2020, Allergan plc (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2019. A copy of the press release reporting the financial results of the Company is attached to this report as Exhibit 99.1 and incorporated herein by reference.
The information in this report (including the exhibits) is furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
|
|
|
|
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: February 10, 2020
|
Allergan plc
|
|
|
|
|
|
|
|
By:
|
|
/s/ Matthew M. Walsh
|
|
|
|
Name:
|
|
Matthew M. Walsh
|
|
|
|
Title:
|
|
EVP & Chief Financial Officer
|
|
Allergan (NYSE:AGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergan (NYSE:AGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
